Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients.
Maria SchwaederleNithya KrishnamurthyGregory A DanielsDavid E PiccioniSantosh KesariPaul T FantaRichard B SchwabSandip P PatelBarbara A ParkerRazelle KurzrockPublished in: Cancer (2017)
Overall, TERT promoter alterations were among the most prevalent aberrations in this population, with very high rates in brain cancers (48% of patients) and melanomas (56% of patients). These aberrations frequently coexist with a high number of other aberrations, with the latter feature also significantly associated with poorer overall survival. Therapeutic options for targeting tumors with TERT promoter mutations are currently limited, although a variety of novel approaches are under development. Cancer 2018;124:1288-96. © 2017 American Cancer Society.
Keyphrases
- end stage renal disease
- papillary thyroid
- dna methylation
- ejection fraction
- newly diagnosed
- copy number
- chronic kidney disease
- gene expression
- transcription factor
- prognostic factors
- squamous cell
- peritoneal dialysis
- squamous cell carcinoma
- deep learning
- multiple sclerosis
- brain injury
- genome wide
- circulating tumor cells